Metformin during Pregnancy in Polycystic Ovary Syndrome: Another Vitamin Bites the Dust | Zendy

Richard S. Legro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metformin during Pregnancy in Polycystic Ovary Syndrome: Another Vitamin Bites the Dust

Author(s) -

Richard S. Legro

Publication year - 2010

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2010-2301

Subject(s) - metformin , polycystic ovary , medicine , pregnancy , insulin resistance , infertility , gestational diabetes , ovulation , preeclampsia , diabetes mellitus , obstetrics , gynecology , endocrinology , gestation , biology , hormone , genetics

The use of metformin in reproductive medicine has exploded since clinical trials showed that a metabolic medication improved reproductive abnormalities in women with polycystic ovary syndrome (PCOS) (1). Metformin soon became an essential element for restoring ovulation (2), curing infertility (3), preventing pregnancy loss (4), and reducing pregnancy complications such as gestational diabetes mellitus (GDM), preeclampsia, and preterm labor, all of which were linked to insulin resistance and systemic inflammation in PCOS (5). Metformin lost the mantel of a medication, to be used judiciously for specific indications, and became instead a new vitamin, vitamin M, to be used ubiquitously to enhance every reproductive process in women with PCOS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research